Vir Biotechnology
CompanyUnited States
Vir Biotechnology develops one asset, in phase 1 (VIR-5500 in metastatic castration-resistant prostate cancer). Mostly antibody acting on CD3E and FOLH1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 2
- Signals
Pipeline
1Dual-masked T-cell engager targeting PSMA and CD3 to direct T cells to prostate cancer cells
Phase 1, Antibody, CD3E, FOLH1, metastatic castration-resistant prostate cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals2
- Similar companies4